Please login to the form below
Dr Reddy's Laboratories
This page shows the latest Dr Reddy's Laboratories news and features for those working in and with pharma, biotech and healthcare.
Amarin shares tumble following Vascepa patent loss
Dr Reddy’s Laboratories and Hikma Pharmaceuticals are already queueing up to launch generic versions of Vascepa, with Hikma reporting that it is working with the FDA to gain approval for ... The patent ruling only applies to Vascepa’s US patent
Latest news
-
GSK and Apotex join generic Zantac recalls as carcinogen concerns mount
Reddy’s Laboratories and Saraca Laboratories. A spokeswoman for GSK, Kristen Neese, reportedly said in an email that Dr. ... Reddy’s has an FDA-approval to sell its own versions of prescription and OTC generic Zantac in the US.
-
Indivior push to diversify boosted by schizophrenia drug approval
The two approvals come as Indivior is fighting a rearguard action to protect Suboxone from a generic developed by Dr Reddy’s Laboratories. ... Reddy’s generic earlier this month.
-
Indivior slumps as patent dispute rises US generic spectre
Indivior said it plans to appeal the decision, which held that three US patents on Suboxone were valid but that a generic from Indian drugmaker Dr Reddy's Laboratories drug does ... He said that Dr Reddy's has not yet been granted FDA approval for its
-
Fresenius Kabi buys Akorn and Merck's biosimilar businesses
Adding in Merck's biosimilars business takes it right back into the biotech sphere. ... Merck kicked off its biosimilar programme in 2012 via an agreement with India's Dr Reddy's Laboratories at a time when the company was facing patent expiries on some
-
Merck confirms sale of biosimilar division
The German group kicked off its biosimilar programme in 2012 via an agreement with India's Dr Reddy's Laboratories, at a time when the company was facing patent expiries on ... At the time the Dr Reddy's deal was announced the biosimilars market was a
More from news
Approximately 1 fully matching, plus 37 partially matching documents found.
Latest Intelligence
-
Deal Watch June 2016
The three deals with Mayne Pharma, Impax Laboratories and Dr Reddy's, for a combined value of over $1.5bn, cover portfolios of marketed and approved generic drugs, drugs currently pending ... acquisition assets/ return of rights. 586. Teva and Allergan/
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
MedImmune appoints Dr Anand Subramony
While at Novartis Dr Subramony established and headed company's novel delivery technologies and therapeutics group. ... Prior to that he held leadership positions at Dr. Reddy's Laboratories in Bridgewater, New Jersey and Johnson &Johnson/Alza
-
New global head of HR for Dr Reddy’s
Sripada Chandrasekhar joins from IBM. Hyderabad, India-headquartered Dr Reddy's Laboratories has appointed a former IBM executive president and global head of human resources. ... Chakraborty remains with Dr Reddy's, and has retained all but the HR
-
Dr Reddy’s appoints Umang Vohra to lead US business
Will be replaced as chief financial officer by Saumen Chakraborty. Indian generics company Dr Reddy's Laboratories has appointed Umang Vohra as the new head of its North American business. ... He first joined the company in 2002, moving from Pepsico-India
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Creabilis names Catherine Moukheibir as chairman of the board
- World Health Organization releases latest set of COVID-19 guidelines
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- MIT researchers develop AI model to detect future lung cancer risk
PMHub
Havas Life Medicom
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
